Join the Encorafenib group to help and get support from people like you.
Encorafenib News
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
TUESDAY, Feb. 4, 2025 – For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate],...
U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE) December 20, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi (encorafenib) in combination with...
FDA Approves Braftovi (encorafenib) with Mektovi (binimetinib) for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation
NEW YORK--(BUSINESS WIRE) October 12, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) + Mektovi® (binimetinib) f...
FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for t...
Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations
BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...
Further information
Related condition support groups
Non-Small Cell Lung Cancer, Colorectal Cancer